Zydus Claims Top Spot In India Biosimilars With Kadcyla, Sees 40-50% Growth
Single-Dose Malaria Drug Moves To Phase II
Executive Summary
Zydus Cadila sees 40-50% growth continuing in its biosimilars business, with plans for launches in Latin America. Its Kadcyla biosimilar is faring well and after helping the company gain the top spot in India, could also move to clinical trials in the US.
You may also be interested in...
Zydus MD On Quest For Novel ADCs, Antibodies Amid Shifting Modalities
Zydus is developing a novel ADC, one of the most challenging but rewarding treatment modalities today as others in the class like Kadcyla and Enhertu prove. The Indian firm's managing director spoke to Scrip about R&D efforts, recent policy moves and gains from making the world’s first approved recombinant plasmid DNA vaccine.
Late To The Antibody-Drug Conjugate Party, But Will 2024 Be A Turning Point For India?
In 2024, Sun Pharma’s ADC candidate is expected to be in human trials, while CDMOs like Piramal Pharma Solutions and Aurigene are to operationalize significant new capacities. But can India compensate for a late start on the ADC journey by tapping low development costs and favorable policies, or is it too little with China far ahead in the race?
India Breast Cancer Drugs Roundup: Trastuzumab Prices Plunge, Enhertu Looms
Glenmark has dropped the price of its trastuzumab biosimilar by over 70% in India. Scrip talks to experts on what that may mean for the competition and also spotlights action around other HER2-directed therapies, including the impending arrival of blockbuster ADC Enhertu.